The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period

Trial Profile

The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Rosiptor (Primary)
  • Indications Interstitial cystitis
  • Focus Registrational; Therapeutic Use
  • Acronyms LEADERSHIP 301
  • Sponsors Aquinox Pharmaceuticals
  • Most Recent Events

    • 12 Mar 2018 According to an Aquinox Pharmaceuticals media release, 341 females and 92 males have been enrolled in this trial.
    • 09 Feb 2018 Status changed from recruiting to active, no longer recruiting, according to an Aquinox Pharmaceuticals media release.
    • 18 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top